Role of intradermal platelet rich plasma in treatment of melasma

Efficacy of intradermal platelet rich plasma in treatment of melasma - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097168

Enrollment

Registered

2025-11-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: NOT APPLICABLE: NOT APPLICABLE Intervention2: AUTOLOGUS PLATELET RICH PLASMA: COMPARATOR AGENT NOT APPLICABLE Intervention3: Autologus Platelet Rich Plasma: Intradermal Autologus Platel

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Melasma who are above 18 Years

Exclusion criteria

Exclusion criteria: Pregnant /Lactating Use Of OCP/Isotretinoin Bleeding Tendencies Recent Laser Treatments Using Bleaching creams

Design outcomes

Primary

Measure	Time frame
1 mMASI score to assess severity of melasma 2 Dermascopic evaluationTimepoint: Treatment administered over 4 weeks interval for 3 sittings	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Shilpa Haibatti Pathrikar

MGM Medical College Aurangabad

drshilpaibatti@gmail.com9527413388

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026